Biosimilar Gene Therapy: Investigational Assessment of Secukinumab Gene Therapy
Objective: Tumor necrosis factor-alpha (TNF-α), checkpoint inhibitors, and interleukin-17 (IL-17) are critical targets in inflammation and autoimmune diseases. Monoclonal antibodies (mAbs) have a successful portfolio in the treatment of chronic diseases. With the current progress in stem cells and...
Main Authors: | Ali Fallah, Hajar Estiri, Elizabeth Parrish, Mansoureh Soleimani, Sirous Zeinali, Azita Zadeh-Vakili |
---|---|
Format: | Article |
Language: | English |
Published: |
Royan Institute (ACECR), Tehran
2019-08-01
|
Series: | Cell Journal |
Subjects: | |
Online Access: | https://celljournal.org/journal/article/fulltext/biosimilar-gene-therapy-investigational-assessment-of-secukinumab-gene-therapy.pdf |
Similar Items
-
Secukinumab – first in class interleukin-17A inhibitor for the treatment of psoriasis
by: Kiran Godse
Published: (2017-01-01) -
Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population
by: Berman J, et al.
Published: (2021-11-01) -
Repression Of TGF-Β Signaling In Breast Cancer Cells By MiR-302/367 Cluster
by: Mona Ahmadalizadeh Khanehsar, et al.
Published: (2019-08-01) -
Secukinumab
by: Nilgün Atakan
Published: (2022-04-01) -
Secukinumab Therapy in Psoriasis Management
by: Ira Yunita, et al.
Published: (2022-03-01)